Coordination of Oral Anticoagulant Care at Hospital Discharge (COACHeD): protocol for a pilot randomised controlled trial

Anne M Holbrook, Kristina Vidug, Lindsay Yoo, Sue Troyan, Sam Schulman, James Douketis, Lehana Thabane, Stephen Giilck, Yousery Koubaesh, Sylvia Hyland, Karim Keshavjee, Joanne Ho, Jean-Eric Tarride, Amna Ahmed, Marianne Talman, Blair Leonard, Khursheed Ahmed, Mohammad Refaei, Deborah M Siegal, Anne M Holbrook, Kristina Vidug, Lindsay Yoo, Sue Troyan, Sam Schulman, James Douketis, Lehana Thabane, Stephen Giilck, Yousery Koubaesh, Sylvia Hyland, Karim Keshavjee, Joanne Ho, Jean-Eric Tarride, Amna Ahmed, Marianne Talman, Blair Leonard, Khursheed Ahmed, Mohammad Refaei, Deborah M Siegal

Abstract

Background: Oral anticoagulants (OACs) are commonly prescribed, have well-documented benefits for important clinical outcomes but have serious harms as well. Rates of OAC-related adverse events including thromboembolic and hemorrhagic events are especially high shortly after hospital discharge. Expert OAC management involving virtual care is a research priority given its potential to reach remote communities in a more feasible, timely, and less costly way than in-person care. Our objective is to test whether a focused, expert medication management intervention using a mix of in-person consultation and virtual care follow-up, is feasible and effective in preventing anticoagulation-related adverse events, for patients transitioning from hospital to home.

Methods and analysis: A randomized, parallel, multicenter design enrolling consenting adult patients or the caregivers of cognitively impaired patients about to be discharged from medical wards with a discharge prescription for an OAC. The interdisciplinary multimodal intervention is led by a clinical pharmacologist and includes a detailed discharge medication reconciliation and management plan focused on oral anticoagulants at hospital discharge; a circle of care handover and coordination with patient, hospital team and community providers; and early post-discharge follow-up virtual medication check-up visits at 24 h, 1 week, and 1 month. The control group will receive usual care plus encouragement to use the Thrombosis Canada website. The primary feasibility outcomes include recruitment rate, participant retention rates, trial resources management, and the secondary clinical outcomes include adverse anticoagulant safety events composite (AASE), coordination and continuity of care, medication-related problems, quality of life, and healthcare resource utilization. Follow-up is 3 months.

Discussion: This pilot RCT tests whether there is sufficient feasibility and merit in coordinating oral anticoagulant care early post-hospital discharge to warrant a full sized RCT.

Trial registration: NCT02777047.

Keywords: Anticoagulation; Hospital discharge; Medication management; Pilot trial; Transitional care.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

References

    1. Institute for Safe Medication Practices (ISMP). Hospital to home - facilitating medication safety at transitions: a toolkit for healthcare providers. Toronto, CA: ISMP; 2015. [Available from: ]. Accessed 3 June 2022.
    1. Moore TCM, Furberg C, Mattison D. QuarterWatch 2013 quarter 1: perspective on drug hypersensitivity; ISMP Canada. ResearchGate. 2014. p. 1–18. 10.13140/RG.2.1.5065.6168.
    1. Bayoumi I, Dolovich L, Hutchison B, Holbrook A. Medication-related emergency department visits and hospitalizations among older adults. Can Fam Physician. 2014;60(4):e217–22.
    1. Budnitz DS, Shehab N, Lovegrove MC, Geller AI, Lind JN, Pollock DA. US emergency department visits attributed to medication harms, 2017-2019. JAMA. 2021;326(13):1299–1309. doi: 10.1001/jama.2021.13844.
    1. Ontario HQ. Transitions between hospital and home: care for people of all ages: HQO; 2020 [Available from: ]. Accessed 10 June 2022.
    1. Holbrook ABH, Paterson M, Martins D, Greaves S, Munil P, Gomes T. Oral anticoagulant-associated adverse event rates are high in the post-hospital discharge period. CMAJ Open. 2021;9(2):364–375. doi: 10.9778/cmajo.20200138.
    1. Graves CM, Haymart B, Kline-Rogers E, Barnes GD, Perry LK, Pluhatsch D, et al. Root cause analysis of adverse events in an outpatient anticoagulation management consortium. Jt Comm J Qual Patient Saf. 2017;43(6):299–307.
    1. Banerjee A, Benedetto V, Gichuru P, Burnell J, Antoniou S, Schilling RJ, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2020;106(2):119–126. doi: 10.1136/heartjnl-2019-315307.
    1. Yu A, Jeyakumar Y, Wang M, Lee J, Marcucci M, Holbrook A. How personalized are benefit and harm results of randomized trials? A systematic review. J Clin Epidemiol. 2020;126:17–25. doi: 10.1016/j.jclinepi.2020.05.029.
    1. Majeed A, Schulman S. Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol. 2013;26(2):191–202. doi: 10.1016/j.beha.2013.07.001.
    1. Moore TCM, Furberg C. Monitoring FDA MedWatch reports: anticoagulants the leading reported drug risk in 2011. Toronto CA: ISMP Quarterwatch; 2011.
    1. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;3:CD001927. doi: 10.1002/14651858.CD001927.pub2.
    1. Ben Freedman S, Gersh BJ, Lip GY. Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. Eur Heart J. 2015;36(11):653–656. doi: 10.1093/eurheartj/ehu494.
    1. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–45 e4. doi: 10.1016/j.amjmed.2009.11.025.
    1. Park SKJN. Nonvalvular Atrial Fibrillation in the Era of Non-Vitamin K Antagonist Oral Anticoagulants. Int J Arrhythmia. 2022;23(1). 10.1186/s42444-021-00053.
    1. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S–ee84S. doi: 10.1378/chest.11-2295.
    1. Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257–3291. doi: 10.1182/bloodadvances.2018024893.
    1. Andrade JG, Verma A, Mitchell LB, Parkash R, Leblanc K, Atzema C, et al. 2018 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2018;34(11):1371–1392. doi: 10.1016/j.cjca.2018.08.026.
    1. Thrombosis Canada Clinical Guide Committee. Clinical Guides 2021: Thrombosis Canada; 2021. [Available from: ]. Accessed 23 June 2022.
    1. De Regge MDPK, Meijboom B, Trybou J, Mortier E, Eekloo K. The role of hospitals in bridging the care continuum: a systemtic review of coordination of care and follow-up for adults with chronic conditions. BMC Health Serv Res. 2017;17(1):550. doi: 10.1186/s12913-017-2500-0.
    1. Tricco ACAJ, Ivers NM, Ashoor HM, Khan PA, Blondal E, Ghassemi M, MacDonald H, Chen MH, Ezer LK, Straus SE. Effectiveness of quality improvement strategies for coordination of care to reduce use of health care services: a systematic review and meta-analysis. CMAJ Open. 2014;186(15):E568–EE78. doi: 10.1503/cmaj.140289.
    1. Huntley ALD, Wye L, Morris R, Checkland K, England H, Salisbury C, et al. Which feaures of primary care affect unscheduled secondary care use? A systematic review. BMJ Open. 2013;4(5):e004746. 10.1136/bmjopen-2013-004746 PMID: 24860000; PMCID: PMC4039790.
    1. Sakunrag I, Danwilai K, Dilokthornsakul P, Chaiyakunapruk N, Dhippayom T. Clinical Outcomes of Telephone Service for Patients on Warfarin: A Systematic Review and Meta-Analysis. Telemed J E Health. 2020;26(12):1507–1521. doi: 10.1089/tmj.2019.0268.
    1. Lee M, Wang M, Liu J, Holbrook A. Do telehealth interventions improve oral anticoagulation management? A systematic review and meta-analysis. J Thromb Thrombolysis. 2018;45(3):325–336. doi: 10.1007/s11239-018-1609-2.
    1. Xia X, Wu J, Zhang J. The effect of online versus hospital warfarin management on patient outcomes: a systematic review and meta-analysis. Int J Clin Pharmacol. 2018;40(6):1420–1429. doi: 10.1007/s11096-018-0731-8.
    1. Lee PA, Greenfield G, Pappas Y. The impact of telehealth remote patient monitoring on glycemic control in type 2 diabetes: a systematic review and meta-analysis of systematic reviews of randomised controlled trials. BMC Health Serv Res. 2018;18(1):495. doi: 10.1186/s12913-018-3274-8.
    1. Ekeland AG, Bowes A, Flottorp S. Effectiveness of telemedicine: a systematic review of reviews. Int J Med Inform. 2010;79(11):736–771. doi: 10.1016/j.ijmedinf.2010.08.006.
    1. Duan-Porter W, Ullman K, Majeski B, Miake-Lye I, Diem S, Wilt TJ. Care coordination models and tools: a systematic review and key informant interviews. [Internet]. Washington (DC): Department of Veterans Affairs (US); 2020 Jun. Available from: . Accessed 15 June 2022.
    1. Michigan Anticoagulation Quality Improvement Initiative. Anticoagulation desktop reference (version 2.0.1): a consortium-developed compendium of anticoagulation information: Michigan Anticoagulation Quality Improvement Initiative (MAQI2); 2020 [updated Septmeber 2 2020. Available from: . Accessed 15 June 2022.
    1. The Joint Commission. R3 Report Issue 19: national patient safety goal for anticoagulant therapy. The Joint Commission; 2018. Available from: . Accessed 3 June 2022.
    1. Chan AW, Tetzlaff JM, Altman DG, Dickersin K, Moher D. SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet. 2013;381(9861):91–92. doi: 10.1016/S0140-6736(12)62160-6.
    1. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. doi: 10.1136/bmj.g1687.
    1. Orkin AM, Gill PJ, Ghersi D, Campbell L, Sugarman J, Emsley R, et al. Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances: the CONSERVE 2021 statement. JAMA. 2021;326(3):257–265. doi: 10.1001/jama.2021.9941.
    1. COACHeD RCT Capacity to Consent Questionnaire. MacSphere. 2021. Available from: . Accessed 15 June 2022.
    1. Institute for Safe Medication Practices Canada. Institute for Safe Medication Practices Canada. Medication Reconciliation (MedRec) ISMPCanada. Toronto CA: ISMPCanada; 2000. [Available from: ]. Accessed 3 June 2022.
    1. Thrombosis Canada. Thrombosis Canada. Canada: Thrombosis Canada. [Available from: ]. Accessed 8 June 2022.
    1. Keshavjee K, Mirza K, Martin K. The next generation EMR. Stud Health Technol Inform. 2015;208:210–214.
    1. Institue for Safe Medication Practices Canada. Virtual medication history interviews and discharge education. Toronto CA: ISMP; 2020. [Available from: ]. Accessed 3 June 2022.
    1. Core elements of anticoagulation stewardship programs 2019: anticoagulation forum; 2019 [Available from: ]. Accessed 10 June 2022.
    1. McMaster's Health Information Research Unit. CLOT Respository: McMaster University; [Available from: ]. Accessed 10 June 2022.
    1. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239. doi: 10.1136/bmj.i5239.
    1. Thabane L, Lancaster G. A guide to the reporting of protocols of pilot and feasibility trials. Pilot Feasibility Stud. 2019;5:37. doi: 10.1186/s40814-019-0423-8.
    1. Wenger NS, Roth CP, Shekelle P, Investigators A. Introduction to the assessing care of vulnerable elders-3 quality indicator measurement set. J Am Geriatr Soc. 2007;55(Suppl 2):S247–S252. doi: 10.1111/j.1532-5415.2007.01328.x.
    1. COACHeD RCT Additional Files 2021 (CCCQ, OAC Knowledge Test, Patient/Caregiver Study Satisfaction Survey). MacSphere, McMaster University. 2021. Available from: . Accessed 8 June 2022.
    1. Euroqol. EQ-5D Instruments: Euroqol; 2018 [Available from: ]. Accessed 15 June 2022.
    1. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20(10):1727–1736. doi: 10.1007/s11136-011-9903-x.
    1. Xie F, Pullenayegum E, Gaebel K, Bansback N, Bryan S, Ohinmaa A, et al. A time trade-off-derived value set of the EQ-5D-5L for Canada. Med Care. 2016;54(1):98–105. doi: 10.1097/MLR.0000000000000447.
    1. Rolls CAOK, Chalmers L, et al. The relationship between knowledge, health literacy, and adherence among patients taking oral anticoagulants for stroke thromboprophyxlaxis in atrial fibrillation. Cardiovasc Ther. 2017;35(6). 10.1111/1755-5922.12304.
    1. Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al. The COMET Handbook: version 1.0. Trials. 2017;18(Suppl 3):280. doi: 10.1186/s13063-017-1978-4.
    1. Perino AC, Shrader P, Turakhia MP, Ansell JE, Gersh BJ, Fonarow GC, et al. Comparison of patient-reported care satisfaction, quality of warfarin therapy, and outcomes of atrial fibrillation: findings from the ORBIT - AF Registry. J Am Heart Assoc. 2019;8(9):e011205. doi: 10.1161/JAHA.118.011205.
    1. National Coordinating Council for Medication Error Reporting and Prevention (NCC-MERP). About Medication Errors: MERP N; 2020 [Available from: ]. Accessed 15 June 2022.
    1. Holbrook A, Pullenayegum E, Thabane L, Troyan S, Foster G, Keshavjee K, et al. Shared electronic vascular risk decision support in primary care: Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness (COMPETE III) randomized trial. Arch Intern Med. 2011;171(19):1736–1744. doi: 10.1001/archinternmed.2011.471.
    1. Carrasquillo O. In: Health Care Utilization. Encyclopedia of Behavioral Medicine. Gellman MD, Turner JR, editors. New York: Springer; 2013. pp. 909–910.
    1. Canadian Agency for Drug and Technogolies in Health (CADTH) [Internet] Canada: Canadian Journal of Health Technologies; 2021 [Available from: ]. Accessed 20 June 2022.
    1. Viechtbauer W, Smits L, Kotz D, Bude L, Spigt M, Serroyen J, et al. A simple formula for the calculation of sample size in pilot studies. J Clin Epidemiol. 2015;68(11):1375–1379. doi: 10.1016/j.jclinepi.2015.04.014.
    1. Wei LJ. The adaptive biased coin design for sequential experiments. Ann Stat. 1978;6(1):92–100. doi: 10.1214/aos/1176344068.
    1. Markaaryan TRW. Exact properties of Efron's biased coin randomization procedure. Ann Statist. 2010;38(3):1546–1567. doi: 10.1214/09-AOS758.
    1. Soares JFJWC. Some restricted randomization rules in sequential designs. Commun Stat. 1983;12(17):2017–2034. doi: 10.1080/03610928308828586.
    1. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
    1. Holbrook A, Wang M, Swinton M, Troyan S, Ho JMW, Siegal DM. Barriers and facilitators for optimizing oral anticoagulant management: perspectives of patients, caregivers, and providers. PLoS One. 2021;16(9):e0257798. doi: 10.1371/journal.pone.0257798.
    1. Wang M, Holbrook A, Lee M, Liu J, Leenus A, Chen N, et al. Barriers and facilitators to optimal oral anticoagulant management: a scoping review. J Thromb Thrombolysis. 2020;50(3):697–714. doi: 10.1007/s11239-020-02056-0.
    1. Wang M, Chen Z, Wong M, Thabane L, Mbuagbaw L, Siegal D, et al. Are the correct outcomes being measured in studies of oral anticoagulants? A systematic survey. Thromb Res. 2021;201:30–49. doi: 10.1016/j.thromres.2021.02.016.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다